Explore By Subject Area   
Return Home
Menu

Lead Podcast

Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process

Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process

Cell therapy manufacturing experts talk about the lessons they've learned through their work, and offer advice on optimizing and streamlining the process.

Read More

Featured Podcasts

Delivery Challenges from the Oncology Pipeline

Read More

Key Learnings from the Clinical Development of Approved Cell Therapy Products

Read More

Addressing the Current Market and Investment Trends in Immuno-Oncology

Read More

Innovative CRISPR Editing to Create Off-the-Shelf Immune Cell Therapies

Read More

More Related Content

Pharmatalk Radio Podcasts

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities
Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach

Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach
Investment Trends for the IO 2.0 Wave

Investment Trends for the IO 2.0 Wave
Investment and Collaboration Strategies in Cell and Gene Therapy

Investment and Collaboration Strategies in Cell and Gene Therapy
Nobel Laureate Dr Gregg Semenza Presents Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors

Nobel Laureate Dr Gregg Semenza Presents Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors
Using Neoadjuvant Immune Checkpoint Blockade as a Window into Treatment Response and Primary Resistance

Using Neoadjuvant Immune Checkpoint Blockade as a Window into Treatment Response and Primary Resistance
Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development
Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment

Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment
What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum

What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum
The Role of Chinese Biotechs in the BD Process for Immuno-Oncology

The Role of Chinese Biotechs in the BD Process for Immuno-Oncology
Understanding Next-Generation Immune Checkpoints and Deciphering Key Roles in the TME

Understanding Next-Generation Immune Checkpoints and Deciphering Key Roles in the TME
Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies

Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies
A Decade After Checkpoints: What Do We Know, What Do We Need to Know?

A Decade After Checkpoints: What Do We Know, What Do We Need to Know?
Achieving Diversity and Inclusion in Oncology Clinical Trials

Achieving Diversity and Inclusion in Oncology Clinical Trials
Advancements in CAR T for the Treatment of Glioblastoma

Advancements in CAR T for the Treatment of Glioblastoma
Cell & Gene Therapy's Current Landscape, Lessons Learned and Paths Forward

Cell & Gene Therapy's Current Landscape, Lessons Learned and Paths Forward
The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health

The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health
HLA Loss and the Impact on Immunotherapy

HLA Loss and the Impact on Immunotherapy
Innovations & Novel Approaches in IO Imaging & Assessing Responses

Innovations & Novel Approaches in IO Imaging & Assessing Responses
Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination
Finding a Life-Saving Nivolumab Trial After a Hodgkin's Lymphoma Diagnosis

Finding a Life-Saving Nivolumab Trial After a Hodgkin's Lymphoma Diagnosis

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.